An Open Label Randomised Trial of RNActive® Cancer Vaccine in High Risk and Intermediate Risk Patients With Prostate Cancer
Stopped Recruitment was terminated after enrolment of 35 instead of 36 evaluable patients for administrative reasons.
Conditions
Interventions
- BIOLOGICAL: CV9104
- DEVICE: needle free injection device (Tropis®)
Sponsor
CureVac